Citigroup Global Markets India (‘Manager to the Offer’), on behalf of Sun Pharmaceutical Industries (‘Sun Pharma’ / ‘Acquirer’), has informed this Announcement to the Shareholders of Zenotech Laboratories (Zenotech / Target Company), pursuant to Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (‘SEBI (SAST) Regulations’) in respect of the open offer (‘Offer’) for acquisition of up to 9,693,332 fully paid up equity shares (‘Shares’) representing 28.16% of the fully diluted share capital of the Target Company and in compliance with Regulations 3(1), 4, and 5(1) of the SEBI (SAST) Regulations. This Announcement should be read in continuation and in conjunction with the Public Announcement dated April 11, 2014 (‘PA’), the Detailed Public Statement with respect to the aforementioned Offer dated March 30, 2015 (‘DPS’) and the Letter of Offer dated June 18, 2015 (‘Letter of Offer’).
The above information is a part of company’s filings submitted to BSE.